Gates Package — page 261
of 1375 pages · Bates Q2 2021
← p.260 p.262 → · this page in the original PDF · package
AstraZeneca
AZD7442
Monoclonal
Intravenous
New
Q3 2021
Antibody
Cocktail
Brii Biosciences
Brii-196 & Brii-
Monoclonal
Intravenous
New
Q2 2021
Antibody
Cocktail
Eli Lilly
LY-CoV-555
Monoclonal
Intravenous
New
Q4 2020
Antibody Single
GSK-Vir
VIR-7831
Monoclonal
Intravenous
New
Q2 2021
Antibody Single
ACTIV-4
Outpatients
BMS/Pfizer
Apixaban
Anticoagulant
Oral
Repurposed
Q4 2021
BMS/Pfizer
Aspirin
Antiplatelet
Oral
Repurposed
4 2021
Inpatients
Other
Un-fractionated
-- Anticoagulant
Intravenous
Repurposed
Q2 2021
(UF) Heparin
Other
Low Molecular
-- Anticoagulant
Injection
Repurposed
Q2 2021
Weight (LMW)
Heparin
ACTIV-5 Inpatient
AbbVie/Boehringer
Risankizumab
Immune
Intravenous
Repurposed
Q4 2021
Ingelheim
Modulator
Humanigen
Lenzilumab
Immune
Intravenous
New
Q4 2021
Modulator
ACTIV-Associated
Adaptive COVID-19 Treatment Trial (ACTT) Inpatient
Gilead
Remdesivir
Antiviral
Intravenous
Repurposed
4 2020
Eli Lilly
Remdesivir and -- Antiviral/Anti-
Intravenous/Oral
Repurposed
Q4 2020
Baricitinib
Inflammatory
Eli Lilly
Remdesivir and
Antiviral/Anti-
Intravenous/Oral
Repurposed
Baricitinib or
Inflammatory/
Dexamethasone
Immune
Modulator
2/3
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/261
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:exh:00154 | — | attachment | 261 |